Nutraceutical product for gastrointestinal well-being

Nutraceutical product, produced from a blend of essential oils of Italian origin, which favors the gastro-intestinal and genitourinary microbial and immune balance.

Title of the patent Miscela di olii essenziali e/o idrolati da piante di origine italiana da applicare allo sviluppo di un nutraceutico per favorire l’equilibrio microbico e immunitario gastro-intestinale e genito-urinario
Thematic area Agro-food
Ownership Pegaso srl, Alma Mater Studiorum – Università di Bologna, Università Cattolica del Sacro Cuore
Inventors Heide De Togni, Maura Di Vito, Paola Mattarelli, Francesca Bugli
Protection Italy (opportunity for seeking international patent protection)
Licensing status Licensed
Keywords Candida spp, probiotics, essential oil, hydrolate, Irritable Bowel Syndrome (IBS), Inflammatory Bowel Diseases (IBD)
Filed on Oct 17, 2018

Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Diseases (IBD) are gastrointestinal disorders associated with abdominal pain, intestinal habitat alteration and relapsing/remitting course. Symptoms are almost the same although with some different manifestations depending on the pathological group to which they belong. Recent studies show that, in these patients, the microbiota is different from the one found in healthy subjects. In fact, some beneficial fungal species (Ascomycetes, particularly Saccharomyces cerevisiae) decrease in percentage when compared to others, even pathogenic, which increase (Basidiomycetes, Candida spp). These do not generate infectious diseases, but are able to alter the normal balance of the gut microbiota.

The product can be considered as an adjuvant able to stimulate the reacquisition of the intestinal physiological microbiota. The mix is a formulation based on essential oils and hydrolates obtained by botanical species entirely cultivated and processed in Italy. Scientific studies conducted on this formulation indicate that the nutraceutical product, besides being safe for human use and able to promote the anti-inflammatory response, is able to inhibit the virulence of C. albicans strains without interfering with the vitality of S. cerevisiae strains. Both microbial species remain vital because the purpose of the formulation is not to disturb the balance by eliminating a species still present in the intestinal microbiota, but to inhibit the pathological species allowing the beneficial ones to regain their territory.

The formulation can be used as a dietary supplement in the diet of patients with IBD and IBS in order to synergize with the medical prescriptions and reduce the symptoms related to pathologies as well as relapses.